Advances in Engineered Biomaterials Targeting Angiogenesis and Cell Proliferation for Cancer Therapy. Issue 12 (14th September 2022)

• Record Type: Journal Article
• Authors: Yadav, Poonam; Dua, Chhavi; Bajaj, Avinash
• Is Part Of: Chemical record. Volume 22:Issue 12(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-14
• Subjects: Cancer -- Angiogenesis -- Nanoparticles -- Hydrogels -- Nanomicelles -- Anticancer Drugs; Chemistry -- Periodicals; 540
• DOI: 10.1002/tcr.202200152
• Languages: English
• ISSNs: 1527-8999

Abstract

Abstract: Antiangiogenic therapy in combination with chemotherapeutic agents is an effective strategy for cancer treatment. However, this combination therapy is associated with several challenges including non‐specific biodistribution leading to systemic toxicity. Biomaterial‐mediated codelivery of chemotherapeutic and anti‐angiogenic agents can exploit their passive and active targeting abilities, leading to improved drug accumulation at the tumor site and therapeutic outcomes. In this review, we present the progress made in the field of engineered biomaterials for codelivery of chemotherapeutic and antiangiogenic agents. We present advances in engineering of liposome/hydrogel/micelle‐based biomaterials for delivery of combination of anticancer and anti‐angiogenesis drugs, or combination of anticancer and siRNA targeting angiogenesis, and targeted nanoparticles. We then present our perspective on developing strategies for targeting angiogenesis and cell proliferation for cancer therapy. Abstract : Biomaterials like liposomes, polymeric nanoparticles, hydrogels, nanomicelles, delivering combination of antiproliferative and antiangiogenesis drugs to tumor tissues via passive or active or localized targeting can improve the cancer treatment, and can reduce drug‐associated toxicity.